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Subarachnoid hemorrhage: epidemiology and 
socioeconomic burden
Subarachnoid  hemorrhage  (SAH)  from  a  ruptured 
intracranial aneurysm is a devastating subset of stroke. 
Intracranial aneurysms are mostly situated on the larger 
arteries supplying the brain. These arteries run through 
the so-called subarachnoid space, which is the very small 
space  between  the  brain  and  the  skull.  If  such  an 
aneurysm  ruptures,  a  bleed  under  arterial  pressure 
occurs  in  this  subarachnoid  space.  Clinically,  patients 
have a sudden, unusual severe headache, which is com-
bined with a sudden loss of consciousness in half of them. 
The mean age at time of SAH is around 50 years, and the 
incidence is around 1 per 10,000 people per year, with 
highest  rates  in  Japan  and  Finland  and  higher  rates  in 
women  than  in  men  [1].  Despite  improvements  in 
patient management and improved prognosis, around a 
third of patients still die in the initial months after the 
hemor  rhage [2].
Because  of  the  relatively  young  age  of  onset  and  its 
poor  prognosis,  the  socioeconomic  burden  of  SAH  is 
considerable. The number of productive life years lost in 
the population from SAH is as large as that lost from 
ischemic stroke [3] and, according to a recent study, a 
total of 80,356 life years and 74,807 quality-adjusted life 
years were lost as a result of SAH in the UK in 2005 [4]. 
Further improvements in prognosis in SAH patients on a 
population level will be difficult to achieve, because one 
in  eight  patients  dies  immediately,  before  reaching  the 
hospital  [5].  Therefore,  prevention  seems  an  attractive 
option to reduce the burden of SAH, and knowledge on 
risk factors is essential for the development of preventive 
measures.
Risk factors for subarachnoid hemorrhage
Risk factors for SAH can be divided into modifiable - or 
environmental - and non-modifiable risk factors. Estab-
lished environmental risk factors for SAH are smoking, 
hypertension  and  excessive  alcohol  intake  [6].  Non-
modifiable risk factors include a familial preponderance 
of  SAH,  female  gender  and  systemic  diseases,  such  as 
polycystic kidney disease and the vascular type of Ehlers 
Danlos disease [7,8]. The familial preponderance suggests 
a genetic component in the risk for SAH. Although SAH 
is  a  rare  disease,  intracranial  aneurysms  are  relatively 
common, with a prevalence of around 1 per 50 people 
[9].  It  therefore  seems  relevant  to  discriminate  risk 
factors for SAH into risk factors for the presence of an 
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presence  of  aneurysms,  atherosclerosis,  a  familial  pre-
pon  derance and polycystic kidney disease are the main 
risk factors. On the other hand, only the size and site of 
the  aneurysm,  age  and  gender  have  been  consistently 
identified as risk factors for rupture of aneurysm. All in 
all,  our  knowledge  of  risk  factors  for  both  the 
development  and  rupture  of  intracranial  aneurysms 
remains rather meager, and hopes are high that genetic 
research will further increase our understanding of such 
risk factors.
Genetic factors for subarachnoid hemorrhage: 
insights from genome-wide association studies
Because both environmental and genetic risk factors have 
a role in SAH and intracranial aneurysms, it is a so-called 
complex  disease.  For  the  identification  of  the  genetic 
factors responsible for a complex disease, candidate gene 
studies were initially used. These studies are hypothesis-
based and genes are selected on the basis of their known 
function and the assumption that they are involved in the 
development of the disease (so-called functional candi-
date genes). The association between the disease and a 
specific allele of a single nucleotide polymorphism (SNP) 
within  the  functional  candidate  genes  is  analyzed 
between patients and controls. In intracranial aneurysms, 
most of these studies included relatively small numbers 
of  patients  and  controls.  Therefore,  results  have  been 
conflicting  or  have  not  been  replicated.  These  studies 
have been reviewed elsewhere [10-12].
A  disadvantage  of  the  hypothesis-based  approach  of 
candidate  gene  studies  is  that  genes  involved  in  the 
pathogenesis of a disease through unknown pathways are 
overlooked.  The  hypothesis-free  approach  by  genome-
wide association studies (GWASs) allow researchers to 
overcome this drawback because in these studies nearly 
all common variation in the entire genome can be tested 
for  association  with  a  disease  [13,14].  In  the  past  few 
years, GWASs have identified hundreds of genetic loci 
contributing to common complex diseases [13,14]. In a 
GWAS the genome is analyzed for common variability 
associated  with  the  risk  of  disease  by  genotyping 
approximately  500,000  SNPs  in  several  thousand  cases 
and  control  participants.  These  genetic  loci  include 
common,  low-risk  variants  (those  that  are  present  in 
more than 5% of the population) that confer a small risk 
of disease, typically with odds ratios (ORs) of 1.2 to 1.5 
[13,15]. However, the variants identified so far by GWAS 
in  relation  to  complex  disease  explain  only  a  small 
proportion  of  the  genetic  risk  for  those  conditions 
[16,17]. For example, the 18 loci associated with type 2 
diabetes explain only about 6% of its heritability [18], and 
the 32 loci associated with Crohn’s disease account for 
20%  of  its  heritability  [19].  Consequently,  the  use  of 
genetic risk prediction and the subsequent opportunities 
for personalized medicine in complex disease are not yet 
possible [20].
The  first  GWAS  of  intracranial  aneurysms  included 
Finnish,  Dutch  and  Japanese  cohorts  making  up  over 
2,100  cases  and  8,000  controls.  Common  SNPs  on 
chromo  somes  2q,  8q  and  9p  showed  a  significant 
association with intracranial aneurysm, with odds ratios 
of  1.24  to  1.36  [21].  In  a  follow-up  GWAS,  additional 
European case and control cohorts were included and the 
original  Japanese  replication  cohort  was  increased, 
resulting in a cohort of 5,891 cases and 14,181 controls 
[22].  This  follow-up  study  identified  three  new  loci 
strongly  associated  with  intracranial  aneurysms  on 
chromo  somes  18q11.2  (OR  =  1.22,  P  =  1.1  ×  10-12), 
13q13.1 (OR = 1.20, P = 2.5 × 10-9) and 10q24.32 (OR = 
1.29, P = 1.2 × 10-9). The previously discovered associa-
tions of 8q11.23-q12.1 (OR = 1.28, P = 1.3 × 10-12) and 
9p21.3 (OR = 1.31, P = 1.5 × 10-22) were replicated [22].
The  8q  locus  contains  a  single  gene,  SOX17,  which 
encodes a transcription factor that has a pivotal role in 
endothelial  cell  function  [23].The  strongest  associated 
SNP within the 9p locus lies close to CDKN2A, which 
encodes the cyclin-dependent kinase inhibitor p16INK4a 
and the alternative open reading frame ARF, a regulator 
of p53 activity, and CDKN2B, which encodes the cyclin-
dependent  kinase  inhibitor  p15INK4b.  In  addition,  a 
non-protein-coding gene (ANRIL) lies within this locus. 
A  recently  described  mutant  mouse  with  a  deletion 
corresponding  to  the  human  9p21  locus  showed  a 
marked suppression of the gene expression of CDKN2B 
and CDKN2A [24]. Aortic smooth-muscle cells in culture 
from these mice showed increased proliferative activity 
compared  with  aortic  smooth-muscle  cells  from  wild-
type mice [24].
The  strongest  associated  SNP  on  the  10q  locus  is 
located within the CNNM2 gene, which encodes cyclin 
M2. Not much is known on its function. The 13q locus 
includes  the  gene  START-domain-containing  13 
(STARD13), of which overexpression leads to suppression 
in  cell  proliferation  [25],  and  the  gene  KLOTHO  (KL). 
KL-deficient  mice  show  extensive  and  accelerated 
arteriosclerosis in association with medial calcification of 
the  aorta  and  both  medial  calcification  and  intimal 
thicken  ing  of  medium-sized  muscular  arteries  [26]. 
Finally, the gene product of RBBP8, located within the 
18q  locus,  is  one  of  the  proteins  that  bind  directly  to 
retinoblastoma protein, which regulates cell proliferation 
[27].  An  important  common  denominator  of  the  gene 
products of the candidate genes in the five intracranial 
loci seems to be involvement in cell proliferation.
Assuming a fourfold increase in the risk of intracranial 
aneurysm  among  siblings  of  cases  [28,29],  the  five 
intracranial  aneurysm  risk  loci  identified  thus  far  only 
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aneurysms [22]. From the results of these two GWASs we 
can  conclude  that,  as  for  other  complex  diseases,  the 
possible development of genetic risk prediction tests also 
remains currently unfeasible for intracranial aneurysms.
Applications for diagnosis: the need for further 
research
So far, the current GWAS findings explain only a small 
proportion of the heritability of complex diseases, includ-
ing the disease SAH and intracranial aneurysms. Further 
research,  including  new  approaches  to  detect  rare 
variants  using  next  generation  sequencing  [30]  and 
structural variants, including copy number variants such 
as insertions and deletions [31], may improve genetic risk 
prediction for SAH and intracranial aneurysms. Know-
ledge  of  the  genetic  determinants  for  intracranial 
aneurysms may provide diagnostic tools for identifying 
individuals at increased risk for aneurysm formation; the 
identified individuals will benefit most from screening by 
imaging studies. Future studies should not only look for 
genetic determinants of intracranial aneurysms, but also 
investigate genetic determinants of rupture of aneurysms. 
Given that only a minority of all unruptured aneurysms 
do  rupture,  these  genetic  determinants  may  provide  a 
powerful  tool  for  identifying  patients  with  unruptured 
aneurysms who are at high risk of rupture and who are 
therefore most likely to benefit from preventive treatment 
of the aneurysm [32].
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